{"id":381860,"date":"2024-07-01T14:00:00","date_gmt":"2024-07-01T12:00:00","guid":{"rendered":"https:\/\/medizinonline.com\/?p=381860"},"modified":"2024-07-05T15:39:42","modified_gmt":"2024-07-05T13:39:42","slug":"post-hoc-analysis-of-the-surpass-studies","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/en\/post-hoc-analysis-of-the-surpass-studies\/","title":{"rendered":"Post-hoc analysis of the SURPASS studies"},"content":{"rendered":"\n

The SURPASS study program investigated the efficacy and safety of the dual GIP\/GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes. An exploratory analysis of the Phase III SURPASS 1-4 studies shows that normoglycemia was achieved in a significant proportion of participants without increasing the risk of hypoglycemia. This was accompanied by an improvement in general metabolic health. These results were published in the journal Diabetes Care <\/em>.<\/strong><\/p>\n\n\n\n

Tirzepatide is the first approved dual GIP\/GLP-1 receptor agonist. The spectrum of action of tirzepatide includes an increase in insulin secretion, a reduction in glucagon and glucose levels, a delay in gastric emptying and a reduction in body weight. The effects are based on agonism at the GIP and GLP-1 receptors. In Switzerland, tirzepatide (Mounjaro\u00ae) has been approved for the treatment of type 2 diabetes since 2022; in the EU and some other regions, the indication for obesity has been extended [1,2]. The medicine is administered once a week as a subcutaneous injection.<\/p>\n\n

Rosenstock et al. analyzed the values by HbA1c<\/sub> category (<5.7%, 5.7-6.5% and >6.5%) of participants who had taken at least 75% of the treatment doses of tirzepatide without rescue medication in SURPASS studies 1-4 (n=3229) [3\u20137]. To assess the impact of patient characteristics on achieving an HbA1c<\/sub> <5.7%, odds ratios were calculated using logistic regression models with tirzepatide as a covariate. It was found that the participants treated with tirzepatide who achieved an HbA1c<\/sub> <5.7% were slightly younger at the start of the study, had a shorter duration of diabetes and a lower HbA1c value<\/sub> (Table 1)<\/strong>. Over the course of the study, these participants also showed greater improvements in HbA1c<\/sub>, body weight, waist circumference, blood pressure, liver enzymes and lipid parameters, without any increase in the risk of hypoglycemia.<\/p>\n

\n
\"\"<\/a><\/figure>\n<\/div>\n

Baseline to week 40: important results at a glance<\/h3>\n\n

The group of patients who achieved an HbA1c<\/sub> value <5.7% at week 40 showed a mean HbA1c change<\/sub> of -3.0% compared to -2.3% in those whose HbA1c<\/sub> value was 5.7-6.5% and compared to -1.1% in patients with an HbA1c<\/sub> value >6.5% (least mean squares<\/em> [LSM]; p<0.001 in each case). The group with an HbA1c value<\/sub> <5.7% achieved a mean body weight reduction of 14.1%, the group with an HbA1c of 5.7-6.5% of 9.6% and in the group with HbA1c<\/sub> >6.5% the weight loss was 5.1% (LSM, p<0.001 in each case). A higher baseline<\/sub> HbA1c (each 1% increase) and fasting glucose (each 50 mg\/dl increase) was associated with a lower likelihood of achieving an HbA1c<\/sub> <5.7% at week 40 (42% and 24%, respectively). In addition, the probability of achieving an HbA1c<\/sub> value <5.7% decreased by 13% and 24% with each 5-year increase in age and diabetes duration, respectively. Only patients receiving metformin had a greater chance of achieving an HbA1c<\/sub> value <5.7%. In terms of adverse event rates, 63% of patients who achieved an HbA1c<\/sub> value <5.7% experienced \u22651 adverse event (AE), while these rates were 62% and 57% in the group of patients who achieved an HbA1c<\/sub> value between 5.7-6.5% and >6.5%, respectively. The most common treatment-related AEs were gastrointestinal complaints (42% vs. 39% and 32% respectively).<\/p>\n\n

Literature:<\/p>\n\n

    \n
  1. Swissmedic: Medicinal product information, www.swissmedicinfo.ch,<\/a>(last accessed 11.06.2024)<\/li>\n\n\n\n
  2. European Commission, https:\/\/ec.europa.eu\/health\/documents\/community-register\/2023\/20231211161235\/anx_161235_en.pdf<\/a>, (last accessed 11.06.2024).<\/li>\n\n\n\n
  3. Rosenstock J, et al: Achieving Normoglycemia With Tirzepatide: Analysis of SURPASS 1-4 Trials. Diabetes Care 2023; 46(11): 1986-1992.<\/li>\n\n\n\n
  4. Rosenstock J, et al.: Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet 2021; 398: 143\u2013155.<\/li>\n\n\n\n
  5. Fr\u00edas JP, et al; SURPASS-2 Investigators . Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med 2021; 385: 503-515.<\/li>\n\n\n\n
  6. Ludvik B, et al: Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomized, open-label, parallel-group, phase 3 trial. Lancet 2021; 398: 583-598.<\/li>\n\n\n\n
  7. Del Prato S, et al; SURPASS-4 Investigators . Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomized, open-label, parallel-group, multicentre, phase 3 trial. Lancet 2021; 398: 1811-1824.<\/li>\n<\/ol>\n\n

    FAMILY PHYSICIAN PRACTICE 2024; 19(6): 31<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

    The SURPASS study program investigated the efficacy and safety of the dual GIP\/GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes. An exploratory analysis of the Phase III SURPASS…<\/p>\n","protected":false},"author":7,"featured_media":127112,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Tirzepatide for type 2 diabetes","footnotes":""},"category":[11508,11384,11297,11548,11503],"tags":[75308,77172,69567,72410,12042],"powerkit_post_featured":[],"class_list":["post-381860","post","type-post","status-publish","format-standard","has-post-thumbnail","category-education","category-endocrinology-and-diabetology","category-general-internal-medicine","category-rx-en","category-studies","tag-mounjaro-en","tag-rosenstock-et-al-en","tag-surpass-en","tag-tirzepatide","tag-type-2-diabetes","pmpro-has-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-04-20 21:38:46","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":381866,"slug":"analyse-post-hoc-des-etudes-surpass","post_title":"Analyse post-hoc des \u00e9tudes SURPASS","href":"https:\/\/medizinonline.com\/fr\/analyse-post-hoc-des-etudes-surpass\/"},"it_IT":{"locale":"it_IT","id":381877,"slug":"analisi-post-hoc-degli-studi-surpass","post_title":"Analisi post-hoc degli studi SURPASS","href":"https:\/\/medizinonline.com\/it\/analisi-post-hoc-degli-studi-surpass\/"},"pt_PT":{"locale":"pt_PT","id":381884,"slug":"analise-post-hoc-dos-estudos-surpass","post_title":"An\u00e1lise post-hoc dos estudos SURPASS","href":"https:\/\/medizinonline.com\/pt-pt\/analise-post-hoc-dos-estudos-surpass\/"},"es_ES":{"locale":"es_ES","id":381779,"slug":"analisis-post-hoc-de-los-estudios-surpass","post_title":"An\u00e1lisis post-hoc de los estudios SURPASS","href":"https:\/\/medizinonline.com\/es\/analisis-post-hoc-de-los-estudios-surpass\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/381860","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/comments?post=381860"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/381860\/revisions"}],"predecessor-version":[{"id":381865,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/381860\/revisions\/381865"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media\/127112"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media?parent=381860"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/category?post=381860"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/tags?post=381860"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/powerkit_post_featured?post=381860"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}